TL;DR
- Dr. Hilary Cass defends the NHS puberty blockers trial.
- The trial aims to assess the impact of puberty blockers on trans youth.
- Political and legal pressures challenge the trial’s ethics.
- Campaigners call for more informed consent practices.
- The trial is set to start in August 2026.
Dr. Hilary Cass is making waves with her defense of the NHS-backed Pathways puberty blockers trial, insisting it’s a vital harm-reduction measure. In a recent BBC interview, she boldly stated, “I am absolutely convinced that more children will be harmed if we don’t do the trial than if we do.” Talk about a hot take!
The Pathways clinical trial is designed to dive deep into the effects of puberty blockers on young participants. Researchers at Kings College London (KCL) are gearing up to explore everything from physical health to emotional wellbeing, including bone density, brain function, and fertility. Sounds like a serious undertaking, right?
But here’s the kicker: the trial is facing mounting political pressure and legal challenges that could throw a wrench in its plans. Cass has pointed out that since the UK introduced restrictions on puberty blockers, the conversation has been clouded with exaggerations about risks. “We genuinely don’t know if there are harms,” she said, emphasizing the need for this trial.
She’s got a point. Without a regulated trial, young people might turn to unregulated and potentially dangerous alternatives to access medication. Cass noted, “Today we have young people turning up in the clinics on testosterone at 11, which we know is irreversible.” Yikes! This trial could give these kids more time for therapeutic support instead of rushing into irreversible decisions.
The Pathways trial was recommended following Cass’s 2024 review of children’s gender medicine, which raised concerns about the weak evidence backing the use of puberty blockers. After a UK-wide ban on prescribing these blockers for children’s gender care, the trial was announced in November 2025. However, it faced a pause in February due to proposed minimum age restrictions for participation.
Now, researchers have settled on minimum ages of 11 for trans male participants and 12 for trans female participants. The trial is expected to kick off in August, pending ongoing legal action. Will it go ahead? Only time will tell!
Health Secretary James Murray has weighed in, expressing his discomfort with the challenges surrounding the trial. He stated, “But for me, following the clinical advice, basing future decisions on clinical evidence, is the right way to move forward in the context of me having received the most robust assurances about the safeguards which are in place to protect young people involved in this trial from receiving harm.” Sounds like he’s trying to play it safe!
But not everyone is on board. Campaigners are bringing legal action against the trial, arguing that it’s unethical and that children can’t give properly informed consent to participate. Chay Brown, healthcare director at TransActual, welcomed the trial but urged the NHS to reverse the puberty blocker ban and provide timely, holistic care for all trans individuals based on informed consent—rather than the latest moral panic.
As the debate heats up, one thing is clear: the Pathways trial is a crucial step in understanding how to best support trans youth in the UK. Will it pave the way for better practices, or will it be derailed by controversy? Stay tuned for updates on this unfolding story!